Log in to save to my catalogue

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignanc...

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignanc...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8facd03b087449c1b612d97fff8f16a9

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had r...

Alternative Titles

Full title

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_8facd03b087449c1b612d97fff8f16a9

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8facd03b087449c1b612d97fff8f16a9

Other Identifiers

ISSN

1756-8722

E-ISSN

1756-8722

DOI

10.1186/s13045-023-01423-7

How to access this item